In the face of chronic disease, DTx have the opportunity to provide a lifeline to patients.
Joel Morse
Advertisement
CEO, Curavit Clinical Research
Articles by Joel Morse
How DCTs can impact pharmaceutical companies exploring DTx combination products and standalone DTx studies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond Patient Centricity: What Rare Disease Research Gets Right
2
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
3
ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD
4
The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness
5